Silverback Therapeutics announced the close of an oversubscribed $78.5 million Series B financing round. U.S. Venture Partners (USVP) led the round, with participation from new investors including Nextech Invest Ltd., Hunt Investment Group, Pontifax Venture Capital, Colt Ventures LP and NS Investment. Along with the financing, Jonathan Root, M.D., general partner at USVP, and Thilo Schroeder, Ph.D., partner at Nextech Invest Ltd., have joined Silverback’s board of directors. Dr. Root spent nine years in clinical practice before joining USVP in 1995 and becoming a general partner in 1997. Dr. Schroeder joined Nextech as a partner in 2012.